Back To Archive

This article may be reprinted free of charge provided 1) that there is clear attribution to the Orthomolecular Medicine News Service, and 2) that both the OMNS free subscription link and also the OMNS archive link are included.

Orthomolecular Medicine News Service, August 30 2023

Breaking Pharma-to-Doctor Kickbacks: India shows the way

by Shalini Mehta

OMNS (August 30, 2023) I live in India, where healthcare providers fall broadly into two categories. One is by way of government run hospitals, which are solely run either by the Central Government or by the State Governments. And then there are private hospitals. The Government Hospitals have well-qualified doctors so the hospitals are loaded to the brim with patients, and they usually do not prescribe medicines to patients which are beyond the pocket reach of the patients, which means mostly generic drugs are prescribed. But every time a patient visits the hospital, it is not necessary he will meet the same doctor that started his/her treatment. Access to Government doctors by patients for outside advice hospitals is not permitted. So many people who can afford to pay considerably larger consultation fees opt for going to private hospitals.

The Indian government has been promoting generic drugs so that medicines are affordable to the general population. A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. So, the Government wants, even in the private hospitals, that doctors should prescribe generic drugs first. Because of close financial connections between doctors and pharma companies, this has not been happening.

Over the last decade, there has been an ever-increasing trend of doctors, in private hospitals, to put patients through a long list of unnecessary lab tests and the prescription of costly drugs. This nexus between doctors, pharma companies and chemists (pharmacists) has been growing out of proportion. As a result, the patients remain at the receiving end - the paying end - increasing the expenditure on healthcare by the general public exponentially.

Finally the National Medical Commission of the Government of India clamped down the pharma-doctor relationship by recently issuing legal notification ( ) on 3rd August, 2023, which clearly states the following:

  1. Registered Medical Practitioners (licenced physicians; RMP) now have to prescribe generic medicines mandatorily instead of brand names. In this decision it clearly states that practitioners shall "Prescribe drugs with "generic"/"non-proprietary"/"pharmacological" names only. In the case of drugs with a narrow therapeutic index, biosimilars, and similar other exceptional cases, this practice can be relaxed."
  2. Physicians may not speak on subjects beyond their area of expertise on social media.
  3. Doctors cannot attend seminars or workshops with direct or indirect funding from pharmaceutical companies.
  4. Furrthermore: "A physician shall not directly or indirectly participate in any act of division, transfer, assignment, subordination, rebating, splitting, or refunding of any fee for diagnostic, scanning, medical, surgical, or other treatment. These provisions shall apply with equal force to the referring, recommending, or procuring by a RMP of any patient, specimen, or material for diagnostic purposes or other studies/work. However, nothing in this section shall prohibit payment of salaries by a qualified RMP to another duly qualified person rendering medical care under his/her supervision. RMP shall not use online forums or agents for procuring patients."
  5. The Government of India's ruling makes it unmistakeably clear that "The RMP cannot endorse a product or person, as in individual capacity or company. RMPs and their families must not receive any gifts, travel facilities, hospitality, cash or monetary grants, consultancy fee or honorariums, or access to entertainment or recreation from pharmaceutical companies or their representatives, commercial healthcare establishments, medical device companies, or corporate hospitals under any pretext."

The maximum action is a suspension of the license to practice for a period ranging from 3 months to 3 years.

I have had two relevant experiences, once with a government doctor and another with a private doctor. When I went for consultation for my condition the doctor first asked me get an MRI done from a specific scanning centre stating that particular scan was only available there. Both times the doctors wrote on a plain paper their recommendation for discount for me as their patient, yet even after the discount the cost was exorbitant. So, the above rrulings will help break interconnections among doctors and diagnostic centres.

I believe this will have a positive effect on the costs related to healthcare in India because in the recent times it has been literally running to the tune of Pharma companies. It is all too well known how to such a great extent pharmaceutical companies have come to virtually run medicine in America. We were worried when we could see that was also repeating in India. With this enactment of these important National Medical Commission regulations, I believe there will be some relief for the general public with this first positive step.

(Shalini Mehta is a postgraduate in Business Administration in Panchkula, Haryana. Some years ago, she began looking for permanent solutions to the health issues she and her family faced. She discovered orthomolecular medicine by attending webinars, reading books, and talking to many integrative medicine practitioners. By introducing nutrition protocols and exercise regimens, her health and the health of her family greatly improved.)

Nutritional Medicine is Orthomolecular Medicine

Orthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more information:

Find a Doctor

To locate an orthomolecular physician near you:

The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource.

Editorial Review Board:

Albert G. B. Amoa, MB.Ch.B, Ph.D. (Ghana)
Seth Ayettey, M.B., Ch.B., Ph.D. (Ghana)
Ilyès Baghli, M.D. (Algeria)
Barry Breger, M.D. (Canada)
Ian Brighthope, MBBS, FACNEM (Australia)
Gilbert Henri Crussol, D.M.D. (Spain)
Carolyn Dean, M.D., N.D. (USA)
Ian Dettman, Ph.D. (Australia)
Susan R. Downs, M.D., M.P.H. (USA)
Ron Ehrlich, B.D.S. (Australia)
Hugo Galindo, M.D. (Colombia)
Gary S. Goldman, Ph.D. (USA)
William B. Grant, Ph.D. (USA)
Claus Hancke, MD, FACAM (Denmark)
Patrick Holford, BSc (United Kingdom)
Ron Hunninghake, M.D. (USA)
Bo H. Jonsson, M.D., Ph.D. (Sweden)
Dwight Kalita, Ph.D. (USA)
Felix I. D. Konotey-Ahulu, M.D., FRCP (Ghana)
Peter H. Lauda, M.D. (Austria)
Fabrice Leu, N.D., (Switzerland)
Alan Lien, Ph.D. (Taiwan)
Homer Lim, M.D. (Philippines)
Stuart Lindsey, Pharm.D. (USA)
Pedro Gonzalez Lombana, M.D., Ph.D. (Colombia)
Victor A. Marcial-Vega, M.D. (Puerto Rico)
Juan Manuel Martinez, M.D. (Colombia)
Mignonne Mary, M.D. (USA)
Joseph Mercola, D.O. (USA)
Jorge R. Miranda-Massari, Pharm.D. (Puerto Rico)
Karin Munsterhjelm-Ahumada, M.D. (Finland)
Sarah Myhill, MB, BS (United Kingdom)
Tahar Naili, M.D. (Algeria)
Zhiyong Peng, M.D. (China)
Isabella Akyinbah Quakyi, Ph.D. (Ghana)
Selvam Rengasamy, MBBS, FRCOG (Malaysia)
Jeffrey A. Ruterbusch, D.O. (USA)
Gert E. Schuitemaker, Ph.D. (Netherlands)
Thomas N. Seyfried, Ph.D. (USA)
Han Ping Shi, M.D., Ph.D. (China)
T.E. Gabriel Stewart, M.B.B.CH. (Ireland)
Jagan Nathan Vamanan, M.D. (India)

Andrew W. Saul, Ph.D. (USA), Editor-In-Chief
Associate Editor: Robert G. Smith, Ph.D. (USA)
Editor, Japanese Edition: Atsuo Yanagisawa, M.D., Ph.D. (Japan)
Editor, Chinese Edition: Richard Cheng, M.D., Ph.D. (USA)
Editor, Norwegian Edition: Dag Viljen Poleszynski, Ph.D. (Norway)
Editor, Arabic Edition: Moustafa Kamel, R.Ph, P.G.C.M (Egypt)
Editor, Korean Edition: Hyoungjoo Shin, M.D. (South Korea)
Editor, Spanish Edition: Sonia Rita Rial, PhD (Argentina)
Editor, German Edition: Bernhard Welker, M.D. (Germany)
Associate Editor, German Edition: Gerhard Dachtler, M.Eng. (Germany)
Assistant Editor: Michael Passwater (USA)
Contributing Editor: Thomas E. Levy, M.D., J.D. (USA)
Contributing Editor: Damien Downing, M.B.B.S., M.R.S.B. (United Kingdom)
Contributing Editor: W. Todd Penberthy, Ph.D. (USA)
Contributing Editor: Ken Walker, M.D. (Canada)
Contributing Editor: Michael J. Gonzalez, N.M.D., Ph.D. (Puerto Rico)
Technology Editor: Michael S. Stewart, B.Sc.C.S. (USA)
Associate Technology Editor: Robert C. Kennedy, M.S. (USA)
Legal Consultant: Jason M. Saul, JD (USA)

Comments and media contact: OMNS welcomes but is unable to respond to individual reader emails. Reader comments become the property of OMNS and may or may not be used for publication.

To Subscribe at no charge:

To Unsubscribe from this list:

Back To Archive

[Home] [History] [Library] [Nutrients] [Resources] [Contact] [Contribute]
Back To Molecule

This website is managed by Riordan Clinic
A Non-profit 501(c)(3) Medical, Research and Educational Organization
3100 North Hillside Avenue, Wichita, KS 67219 USA
Phone: 316-682-3100; Fax: 316-682-5054
© (Riordan Clinic) 2004 - 2024c

Information on is provided for educational purposes only. It is not intended as medical advice.
Consult your orthomolecular health care professional for individual guidance on specific health problems.